H. Heinze

发表

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

A. Forbes, K. Iyer, D. Seidner, 2012, Gastroenterology.

Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease

L. Kupčinskas, S. Kaspari, H. Heinze, 2005, European journal of gastroenterology & hepatology.

Histology and safety parameters during long-term maintenance with pantoprazole in severe acid-peptic disease

H. Heinze, A. Schneider, R. Fischer, 1998 .

Reliable Acid Suppression with Pantoprazole Contrasts with Rapid Development of Tolerance to Ranitidine in Healthy Individuals

R. Pfützer, M. Singer, H. Heinze, 2001 .

Lack of Interaction between Pantoprazole and Ethanol

R. Pfützer, M. Singer, H. Heinze, 2001 .

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.

A. Forbes, B. Messing, M. Pertkiewicz, 2013, Clinical nutrition.

Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL™) scale.

A. Forbes, K. Fragkos, B. Messing, 2013, Clinical nutrition.

In Vitro Immunomodulatory Effects of the Thrombocytic Protein C 24

H. Mohr, H. Heinze, A. Klein-Struckmeier, 1990 .

Teduglutide, a Novel Analogue of Glucagon-like Peptide 2 (GLP-2), Is Effective and Safe in Reducing Parenteral Support Volume in Short Bowel Syndrome–Intestinal Failure Subjects: Results From a 24-Week, Placebo-Controlled Phase 3 Trial (STEPS)

D. Seidner, S. O'keefe, M. Pertkiewicz, 2011 .